ReviewOncoimmunology
Trial Watch: Adoptive cell transfer for anticancer immunotherapy.
Review in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Current and future immunotherapies for NSCLC.Journal of hematology & oncology · 2026Review
- Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Experimental hematology & oncology · 2025Review
- Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy.Journal of clinical medicine · 2022Review
- Improvement in diagnostic and therapeutic arthrocentesis via constant compression.Clinical rheumatology · 2018Article
- Potential impact of invasive surgical procedures on primary tumor growth and metastasis.Clinical & experimental metastasis · 2018Review
- Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.Oncoimmunology · 2016Article
- Trial Watch-Immunostimulation with cytokines in cancer therapy.Oncoimmunology · 2016Review
- Trial Watch-Oncolytic viruses and cancer therapy.Oncoimmunology · 2016Review
- Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination.Frontiers in immunology · 2016Review
- Trial Watch: Adoptive cell transfer for oncological indications.Oncoimmunology · 2015Review
- T cell therapies-are T memory stem cells the answer?Annals of translational medicine · 2015Article
- T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.Oncoimmunology · 2015Article
- Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.Oncoimmunology · 2015Article
- Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.Oncoimmunology · 2015Review
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.Oncoimmunology · 2015Review
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.Cancer gene therapy · 2015Review
- Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors.Journal for immunotherapy of cancer · 2015Article
- Chimeric antigen receptor-engineered T cells as oncolytic virus carriers.Molecular therapy oncolytics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression "adoptive cell transfer" (ACT) is commonly employed to indicate an immunotherapeutic regimen involving the isolation of autologous blood-borne or tumor-infiltrating lymphocytes, their selection/expansion/activation ex vivo, and their reinfusion into the patient, most often in the context of lymphodepleting pre-conditioning and in combination with immunostimulatory treatments. Optionally, the cellular material for ACT is genetically manipulated before expansion to (1) target specific tumor-associated antigens; (2) endogenously express immunostimulatory molecules; and/or (3) persist for long periods upon reinfusion. Consistent efforts have been dedicated at the amelioration of this immunotherapeutic regimen throughout the past decade, resulting in the establishment of ever more efficient and safer ACT protocols. Accordingly, the number of clinical trials testing ACT in oncological indications does not cease to increase. In this Trial Watch, we summarize recent developments in this exciting area of research, covering both high-impact studies that have been published during the last 12 months and clinical trials that have been launched in the same period to evaluate the safety and therapeutic potential of ACT in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.